Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Public ClinicalTrials.gov record NCT01476787. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.
Study identification
- NCT ID
- NCT01476787
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,030 participants
Conditions and interventions
Conditions
Interventions
- Rituximab Drug
- Lenalidomide Drug
- Rituximab-CHOP Drug
- Rituximab-CVP Drug
- Rituximab-Bendamustine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2011
- Primary completion
- Apr 29, 2024
- Completion
- Apr 29, 2024
- Last update posted
- May 13, 2025
2011 – 2024
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 54103 | Chandler | Arizona | 85224 | — |
| Local Institution - 51803 | Fullerton | California | 92835 | — |
| Local Institution - 52003 | Los Angeles | California | 90095 | — |
| Local Institution - 51603 | Colorado Springs | Colorado | 80909 | — |
| Local Institution - 52503 | Englewood | Florida | 34223 | — |
| Local Institution - 51703 | Orlando | Florida | 32806 | — |
| Local Institution - 53803 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 50803 | Chicago | Illinois | 60657 | — |
| Local Institution - 52203 | Lexington | Kentucky | 40536 | — |
| Local Institution - 53603 | Westminster | Maryland | 21157 | — |
| Local Institution - 50403 | Boston | Massachusetts | 02114 | — |
| Local Institution - 50503 | Boston | Massachusetts | 02114 | — |
| Local Institution - 53003 | Southfield | Michigan | 48075 | — |
| Local Institution - 51003 | St Louis | Missouri | 63110 | — |
| Local Institution - 54403 | Cherry Hill | New Jersey | 08003 | — |
| Local Institution - 53703 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 50903 | Morristown | New Jersey | 07960 | — |
| Local Institution - 54303 | Sparta | New Jersey | 07871 | — |
| Local Institution - 52403 | New York | New York | 10019 | — |
| Local Institution - 50203 | New York | New York | 10021 | — |
| Local Institution - 51303 | Nashville | Tennessee | 37203 | — |
| Local Institution - 51203 | Dallas | Texas | 75246 | — |
| Local Institution - 51103 | Houston | Texas | 77030 | — |
| Local Institution - 54003 | Lubbock | Texas | 79410 | — |
| Local Institution - 53303 | Richmond | Virginia | 23230 | — |
| Local Institution - 52703 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01476787, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2025 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01476787 live on ClinicalTrials.gov.